| Name | Arbor Post Acute |
|---|---|
| Location | 1200 Springfield Drive, Chico, California |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 144 |
| Occupancy Rate | 83.82% |
| Medicare ID (CCN) | 555304 |
| Legal Business Name | Arbor Post Acute Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1306894258 |
| Organization Name | EVERGREEN AT CHICO, L.L.C. |
| Doing Business As | TWIN OAKS POST ACUTE REHAB |
| Address | 1200 Springfield Dr, Chico, CA 95928 |
| Phone Number | 530-342-4885 |
News Archive
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Legislation that would promote the adoption and standardization of health information technology is "knotted up" in Congress over privacy issues, CQ Today reports (Wayne, CQ Today, 6/2).
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
› Verified 2 days ago
| NPI Number | 1689179798 |
| Organization Name | ARBOR POST ACUTE, LLC |
| Doing Business As | ARBOR POST ACUTE |
| Address | 1200 Springfield Dr, Chico, CA 95928 |
| Phone Number | 801-447-9829 |
News Archive
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Legislation that would promote the adoption and standardization of health information technology is "knotted up" in Congress over privacy issues, CQ Today reports (Wayne, CQ Today, 6/2).
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
› Verified 2 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Legislation that would promote the adoption and standardization of health information technology is "knotted up" in Congress over privacy issues, CQ Today reports (Wayne, CQ Today, 6/2).
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
› Verified 2 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 3 |
| Total Amount of Fines in Dollars | $45349 |
| Number of Payment Denials | 1 |
| Total Number of Penalties | 4 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 4.33 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 10.62 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 25.6 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 0.2 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 0 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 0.27 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 4 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 100 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 14.32 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 99.61 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0.63 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 13.42 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 14.9 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 13.88 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.33 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 65.34 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 93.53 | 82.93 |
News Archive
Amid the coronavirus disease (COVID-19) outbreak, scientists from around the globe race to fight the deadly virus. Now, a team of Harvard scientists has joined forces with Chinese experts to develop new therapies and prevent the further spread of the virus.
Legislation that would promote the adoption and standardization of health information technology is "knotted up" in Congress over privacy issues, CQ Today reports (Wayne, CQ Today, 6/2).
Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.
Rib-X Pharmaceuticals, Inc., today announced that the Food and Drug Administration (FDA) designated delafloxacin as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
› Verified 2 days ago
Riverside Convalescent Hospital Location: 375 Cohasset Rd, Chico, California 95926 Phone: (530) 343-5595 | |
Windsor Chico Creek Care And Rehab Center Location: 587 Rio Lindo Avenue, Chico, California 95926 Phone: (530) 345-1306 | |
California Park Rehabilitation Hospital Location: 2850 Sierra Sunrise Terrace, Chico, California 95928 Phone: (530) 894-1010 |